BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Stock analysts at William Blair increased their FY2019 EPS estimates for BioDelivery Sciences International in a note issued to investors on Wednesday, November 13th, Zacks Investment Research reports. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings per share of $0.02 for the year, up from their previous estimate of ($0.08). William Blair has a “Buy” rating on the stock. William Blair also issued estimates for BioDelivery Sciences International’s Q4 2019 earnings at $0.01 EPS, Q1 2020 earnings at $0.02 EPS, Q2 2020 earnings at $0.04 EPS and Q3 2020 earnings at $0.06 EPS.
A number of other analysts have also commented on BDSI. Janney Montgomery Scott reissued a “buy” rating on shares of BioDelivery Sciences International in a research note on Wednesday, November 13th. ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Tuesday. LADENBURG THALM/SH SH lifted their price target on BioDelivery Sciences International from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. TheStreet raised BioDelivery Sciences International from a “d” rating to a “c” rating in a research note on Friday, November 22nd. Finally, BidaskClub raised BioDelivery Sciences International from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 16th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. BioDelivery Sciences International presently has an average rating of “Buy” and a consensus target price of $6.50.
NASDAQ:BDSI opened at $6.70 on Monday. The stock’s 50-day simple moving average is $5.94 and its 200 day simple moving average is $4.75. BioDelivery Sciences International has a twelve month low of $2.80 and a twelve month high of $7.01. The firm has a market capitalization of $605.16 million, a PE ratio of -9.18 and a beta of 0.49. The company has a quick ratio of 2.02, a current ratio of 2.25 and a debt-to-equity ratio of 0.86.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.34. The business had revenue of $30.31 million for the quarter, compared to analyst estimates of $28.86 million. BioDelivery Sciences International had a negative return on equity of 8.80% and a negative net margin of 22.11%.
Hedge funds have recently modified their holdings of the business. Mackay Shields LLC increased its holdings in BioDelivery Sciences International by 65.7% in the third quarter. Mackay Shields LLC now owns 605,900 shares of the specialty pharmaceutical company’s stock worth $2,551,000 after purchasing an additional 240,200 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in BioDelivery Sciences International by 1,019.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 186,409 shares of the specialty pharmaceutical company’s stock worth $867,000 after purchasing an additional 169,757 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in BioDelivery Sciences International in the second quarter worth approximately $1,395,000. River & Mercantile Asset Management LLP bought a new stake in BioDelivery Sciences International in the second quarter worth approximately $1,860,000. Finally, Northern Trust Corp increased its holdings in BioDelivery Sciences International by 39.8% in the second quarter. Northern Trust Corp now owns 258,748 shares of the specialty pharmaceutical company’s stock worth $1,203,000 after purchasing an additional 73,637 shares in the last quarter. Institutional investors and hedge funds own 69.44% of the company’s stock.
In other news, CEO Herm Cukier sold 38,461 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.82, for a total transaction of $262,304.02. Following the completion of the transaction, the chief executive officer now directly owns 74,842 shares in the company, valued at $510,422.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott M. Plesha sold 25,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $6.21, for a total value of $155,250.00. Insiders have sold 4,466,650 shares of company stock valued at $26,391,760 over the last 90 days. 8.94% of the stock is owned by corporate insiders.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Recommended Story: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioDelivery Sciences International and related companies with MarketBeat.com’s FREE daily email newsletter.